Figure 4.

IFN-γ suppresses PER2 through its cognate receptor but does not act through canonical pathways. (A) Detrended PER2^LUC traces from mPer2^Luc, mPer2^LucIFN(α/β,γ)R^+/−, or mPer2^LucIFN(α/β,γ)R^−/− BMDMs treated with mock or IFN-γ (50 ng/mL for 24 h). (B) PER2^LUC traces from mPer2^Luc BMDMs treated with mock, IFN-γ, JAK2 inhibitor, or IFN-γ plus JAK2 inhibitor. (C) PER2^LUC traces from mPer2^Luc BMDMs treated with mock, IFN-γ, STAT1 inhibitor, or IFN-γ plus STAT1 inhibitor. (D) PER2^LUC traces from mPer2^Luc BMDMs treated with mock, IFN-γ, MEK inhibitor, or IFN-γ plus MEK inhibitor. Data are represented as mean (n = 3–4). P-values (*) are calculated from one-way ANOVA with post-hoc Tukey tests at the acrophase and are considered to be significantly different with P < 0.05.